-
Mashup Score: 5
To our knowledge, this is the first randomised trial for metachronous PET-detected nodal recurrences comparing two local treatment approaches (MDT and ENRT) in combination with 6 months of androgen deprivation therapy. By showing an improved metastasis-free survival with ENRT, this trial establishes ENRT as a potential standard treatment approach, awaiting a phase 3 trial confirming these results.
Source: www.thelancet.comCategories: General Medicine NewsTweet
-
Mashup Score: 7ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial - 2 month(s) ago
To our knowledge, the RADIOSA trial represents the first randomised trial in the metachronous oligometastatic hormone-sensitive prostate cancer setting to report improved clinical progression-free survival with the combination of SBRT and a short course of ADT, although carefully selected patients might still benefit from SBRT alone. By demonstrating improved clinical progression-free survival, the RADIOSA trial reinforces the role of metastasis-directed therapy in delaying systemic treatment escalation.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Congrats to @GiuliaMarvaso84 @BarbaraJereczek @piet_ost @ChadTangMD on the RADIOSA trial, which randomized patients with omHSPC to SBRT vs. SBRT+6 months ADT https://t.co/xxWeel7rJH
-
-
Mashup Score: 86
Acute toxicity following prostate radiotherapy was statistically significantly associated with late toxicity and with decrement in patient-reported QOL metrics. These data support efforts to evaluate whether interventions that reduce acute toxicity ultimately reduce the risk of late toxicity.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Proud to share work led by John Nikitas PGY-5 @UCLAHealth out in @TheLancetOncol https://t.co/5p13rBLhPx We leveraged toxicity data from 6 trials in the MARCAP consortium to establish a clear link between acute toxicity and late toxicity following prostate radiotherapy
-
-
Mashup Score: 86
Acute toxicity following prostate radiotherapy was statistically significantly associated with late toxicity and with decrement in patient-reported QOL metrics. These data support efforts to evaluate whether interventions that reduce acute toxicity ultimately reduce the risk of late toxicity.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Proud to share work led by John Nikitas PGY-5 @UCLAHealth out in @TheLancetOncol https://t.co/5p13rBLhPx We leveraged toxicity data from 6 trials in the MARCAP consortium to establish a clear link between acute toxicity and late toxicity following prostate radiotherapy
-
-
Mashup Score: 86
Acute toxicity following prostate radiotherapy was statistically significantly associated with late toxicity and with decrement in patient-reported QOL metrics. These data support efforts to evaluate whether interventions that reduce acute toxicity ultimately reduce the risk of late toxicity.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Proud to share work led by John Nikitas PGY-5 @UCLAHealth out in @TheLancetOncol https://t.co/5p13rBLhPx We leveraged toxicity data from 6 trials in the MARCAP consortium to establish a clear link between acute toxicity and late toxicity following prostate radiotherapy
-
-
Mashup Score: 82
Acute toxicity following prostate radiotherapy was statistically significantly associated with late toxicity and with decrement in patient-reported QOL metrics. These data support efforts to evaluate whether interventions that reduce acute toxicity ultimately reduce the risk of late toxicity.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Proud to share work led by John Nikitas PGY-5 @UCLAHealth out in @TheLancetOncol https://t.co/5p13rBLhPx We leveraged toxicity data from 6 trials in the MARCAP consortium to establish a clear link between acute toxicity and late toxicity following prostate radiotherapy
-
-
Mashup Score: 25
JCO PO author Dr. Amar U. Kishan, Professor, Executive Vice Chair, and Chief of Genitourinary Oncology Service in the Department of Radiation Oncology at the University of California, Los Angeles, shares insights into his JCO PO article, “Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study.” Host Dr. Rafeh Naqash and Dr. Kishan discuss the relationship between Decipher genomic classifier scores and prostate-specific membrane antigen (PSMA) PET/CT-based metastatic spread.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Happy to join the JCO Precision Oncology Conversations podcast https://t.co/hlh7YjfpWG to discuss our recent publication https://t.co/g1NPF8IJS5. @JCOPO_ASCO @thenasheffect
-
-
Mashup Score: 25
JCO PO author Dr. Amar U. Kishan, Professor, Executive Vice Chair, and Chief of Genitourinary Oncology Service in the Department of Radiation Oncology at the University of California, Los Angeles, shares insights into his JCO PO article, “Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study.” Host Dr. Rafeh Naqash and Dr. Kishan discuss the relationship between Decipher genomic classifier scores and prostate-specific membrane antigen (PSMA) PET/CT-based metastatic spread.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Happy to join the JCO Precision Oncology Conversations podcast https://t.co/hlh7YjfpWG to discuss our recent publication https://t.co/g1NPF8IJS5. @JCOPO_ASCO @thenasheffect
-
-
Mashup Score: 110Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial - 7 month(s) ago
Image-guided adaptive radiotherapy allowed bladder tumour radiotherapy dose escalation without a significant increase in toxicity. The use of multiple adaptive plans suggests an on-going need for radiotherapy optimisation with adaptive therapy. Dose escalation achieves promising tumour control with low salvage cystectomy rates.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet-
RAIDER trial out in @EUplatinum https://t.co/jTF4TZhP5A Congrats to @robert_huddart @EmmaHall71 @achoud72 on this large trial of bladder preservation with innovative exploration of adaptive therapy. Extremely low rates of grade 3 toxicity and salvage cystectomy
-
-
Mashup Score: 108Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial - 7 month(s) ago
Image-guided adaptive radiotherapy allowed bladder tumour radiotherapy dose escalation without a significant increase in toxicity. The use of multiple adaptive plans suggests an on-going need for radiotherapy optimisation with adaptive therapy. Dose escalation achieves promising tumour control with low salvage cystectomy rates.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet-
RAIDER trial out in @EUplatinum https://t.co/jTF4TZhP5A Congrats to @robert_huddart @EmmaHall71 @achoud72 on this large trial of bladder preservation with innovative exploration of adaptive therapy. Extremely low rates of grade 3 toxicity and salvage cystectomy
-
RT @piet_ost: Link to full paper: https://t.co/iJjDmaJFAR